Valneva SE Form 6-K Summary: Six Months Ended June 30, 2025
Business Context and Reporting Period
This Form 6-K reports the unaudited interim condensed consolidated financial statements and management discussion for Valneva SE, a specialty vaccine company, for the six months ended June 30, 2025. The report was filed on August 12, 2025. Valneva develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, currently marketing three proprietary travel vaccines (IXIARO, DUKORAL, IXCHIQ) and advancing a pipeline including a Lyme disease vaccine (VLA15) in partnership with Pfizer.
Key Financial Metrics
| Metric (€ thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Total Revenues | 97,562 | 70,813 |
| Product Sales | 91,020 | 68,279 |
| Profit/(Loss) for the Period | (20,818) | 33,976 |
| Adjusted EBITDA | (6,020) | 56,159 |
| Cash and Cash Equivalents | 161,307 | 131,413 |
| Total Borrowings | 168,385 | 187,373 |
| Net Cash Used in Operating Activities | (10,943) | (66,261) |
Margins: Gross margin on commercial product sales (excluding IXCHIQ) improved to 59.2% in H1 2025 from 47.7% in H1 2024, driven by better manufacturing performance.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 38% to €97.6 million, driven by a 33% increase in product sales. IXIARO sales grew 31% (€54.7M), DUKORAL grew 16% (€17.4M), and IXCHIQ surged to €7.5M from €1.0M due to an outbreak in La Réunion.
- Profitability Shift: The company reported a net loss of €20.8 million compared to a net profit of €34.0 million in H1 2024. The prior year's profit was significantly inflated by a one-time net gain of €90.8 million from the sale of a Priority Review Voucher (PRV), which did not recur in 2025.
- Operating Expenses: Operating expenses decreased slightly to €118.9 million from €121.3 million. R&D expenses increased to €32.4 million (vs. €29.7M) due to the Shigella vaccine collaboration, while SG&A expenses were reduced through lower recruitment and advisory spending.
- Liquidity and Financing: Cash used in operating activities improved significantly (€10.9M outflow vs. €66.3M outflow). The company raised €20.1 million net proceeds via its At-The-Market (ATM) program in April and May 2025. Total borrowings decreased to €168.4 million, primarily due to foreign exchange gains on USD-denominated debt.
Guidance, Outlook, and Risks
Operational Outlook: Valneva aims to progress the Phase 3 VALOR study for its Lyme vaccine (VLA15) with Pfizer, targeting a Biologics License Application (BLA) submission in 2026. The company plans to secure label extensions for IXCHIQ in the U.S., UK, and Canada and continue Phase 2 trials for the Shigella vaccine (S4V2).
Strategic Updates:
- Secured a €32.8 million contract with the U.S. Department of Defense for IXIARO supply.
- Entered an exclusive distribution agreement with CSL Seqirus for Germany, launching IXCHIQ in July 2025 and other products in 2026.
- Received marketing authorization for IXCHIQ in Brazil, the first approval in an endemic country.
Risks and Contingencies:
- Regulatory/Safety: Temporary restrictions on IXCHIQ use in elderly populations (65+) were lifted by the FDA and EMA in July/August 2025 following investigations into serious adverse events, though updated prescribing information now reflects these risks.
- Partnership Dependence: Valneva relies heavily on Pfizer for the development and commercialization of VLA15; failure of this partnership or negative Phase 3 results would be critical.
- Debt Covenants: The company is subject to minimum revenue (€115M rolling 12-month) and liquidity (€35M) covenants under its Deerfield & OrbiMed loan agreement, with repayments beginning in 2026.
- Geopolitical: Potential 15% tariffs on pharmaceutical imports to the U.S. from Europe could impact costs.
Key Facts for Investor Verification
- IXCHIQ Safety Profile: Verify the long-term impact of the temporary FDA/EMA restrictions on elderly patients on future sales volumes and market perception.
- VLA15 Phase 3 Timeline: Confirm the status of the VALOR trial data readout and the feasibility of the 2026 regulatory submission target with Pfizer.
- Debt Service Capacity: Assess the company's ability to meet the €115M rolling revenue covenant and prepare for debt repayments commencing in 2026 given the current net loss position.
- Inventory Write-downs: Review the €36.3 million inventory write-down provision, specifically the €17.2 million related to the discontinued COVID-19 vaccine (VLA2001) and the remaining provisions for IXIARO, DUKORAL, and IXCHIQ.
- Third-Party Sales Wind-down: Monitor the execution of the plan to reduce third-party sales to less than 5% of total revenue by 2026/2027 to improve gross margins.